UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Biologic treatments for idiopathic inflammatory myopathies
  • Publication Type:
    Chapter
  • Authors:
    Fasano S, Isenberg DA
  • Publication date:
    01/01/2016
  • Pagination:
    45, 56
  • ISBN-13:
    9781634852746
  • Status:
    Published
  • Book title:
    Biologics in Rheumatology: New Developments, Clinical Uses and Health Implication
Abstract
The idiopathic inflammatory myopathies are a group of acquired, heterogeneous, systemic diseases of skeletal muscle. As these conditions are uncommon, current treatment of myositis is based mainly on case reports and few randomised studies with small numbers of patients enrolled. Therefore, the current treatment paradigm is still relies primarily on clinical experience. High dose corticosteroids continue to be the first line therapy. In order to avoid side effects, the prednisolone dose should be reduced based on patient’s clinical response. Other immunosuppressive drugs are used in refractory cases, as well as steroid-sparing agents. Nevertheless, a Cochrane review concluded that there was insufficient evidence from the available studies to confirm the value of immunosuppressive agents in myositis. In patients with myositis resistant to conventional treatment, rituximab is a potential treatment option. Several agents could be of interest for future studies of myositis treatment; however more randomised controlled trials are needed to identify eligibility criteria, outcome predictors and the adequate regimen. The identification of responsive patients and specific therapies targeting the correct myositis subset may be cost-effective and potentially prevent incorrect use of biologics.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by